收缩压降低并保持稳定作为脑出血治疗新目标:ATACH 2 与 INTERACT 2 试验汇总分析结果
该汇总分析纳入ATACH 2和INTERACT 2两项大型跨国临床试验中初始收缩压150–220 mmHg的3694例脑出血患者,定义「收缩压降低并保持稳定」为随机化后1小时内连续记录达到并维持收缩压130–150 mmHg。仅28.7%患者(1061例)在1小时内达到该目标。校正初始收缩压、格拉斯哥昏迷评分、年龄、性别、卒中史、高血压、糖尿病、研究、出血部位、血肿体积及脑室内出血后,达到该目标与90天功能独立(改良Rankin量表0–2分)几率升高相关(OR 1.38,95%CI 1.16–1.64),与24小时内神经功能恶化几率降低相关(OR 0.68,95%CI 0.53–0.88)。作者认为收缩压降低并保持稳定是未来脑出血临床试验有价值的治疗目标。
要点
- 初始收缩压150–220 mmHg的脑出血患者,1小时内达到并维持收缩压130–150 mmHg者仅28.7%(1061/3694)。
- 达到该目标与90天功能独立(改良Rankin量表0–2分)几率升高相关(OR 1.38,95%CI 1.16–1.64)。
- 达到该目标与24小时内神经功能恶化几率降低相关(OR 0.68,95%CI 0.53–0.88)。
- 美国心脏协会/美国卒中协会推荐在启动治疗后60分钟内达到收缩压目标,强调避免「过度」纠正和收缩压波动。
- 作者认为收缩压降低并保持稳定是未来脑出血临床试验有价值的治疗目标。
适用人群与场景
- ATACH 2和INTERACT 2两项试验中初始收缩压150–220 mmHg的脑出血患者,共3694例(INTERACT 2组2781例,ATACH 2组913例)。
- 患者平均年龄63.3±12.9岁,基线收缩压177.14±18.28 mmHg,血肿体积中位数10.78 mL(四分位距5.5–19.16)。
- 原文描述为轻中度脑出血患者。
诊断标准与关键阈值
- 收缩压降低并保持稳定:随机化后第1小时内基于连续记录达到并维持收缩压130–150 mmHg。
- 功能独立:90天改良Rankin量表0–2分。
- 神经功能恶化:24小时内发生。
研究设计与关键结果
- 研究类型:ATACH 2与INTERACT 2两项大型跨国临床试验的汇总分析。
- 样本量:3694例脑出血患者,其中INTERACT 2组2781例、ATACH 2组913例。
- 暴露:随机化后1小时内达到收缩压降低并保持稳定(收缩压130–150 mmHg)者1061例(28.7%)。
- 主要终点:校正初始收缩压、格拉斯哥昏迷评分、年龄、性别、卒中史、高血压、糖尿病、研究、出血部位、血肿体积及脑室内出血后,达到该目标与90天功能独立几率升高相关(OR 1.38,95%CI 1.16–1.64)。
- 关键次要终点:达到该目标与24小时内神经功能恶化几率降低相关(OR 0.68,95%CI 0.53–0.88)。
证据类型、等级与局限
- 证据类型:两项大型跨国临床试验(ATACH 2、INTERACT 2)数据的汇总分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 美国心脏协会/美国卒中协会推荐在启动治疗后60分钟内达到收缩压治疗目标,强调避免「过度」纠正和收缩压波动。
- 作者认为收缩压降低并保持稳定是未来脑出血临床试验有价值的治疗目标。
指南或共识出处
- 美国心脏协会/美国卒中协会推荐:脑出血启动治疗后60分钟内达到收缩压目标,避免「过度」纠正和收缩压波动。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The American Heart Association/American Stroke Association recommends achieving systolic blood pressure (SBP) therapeutic targets within 60 min of initiating treatment for intracerebral hemorrhage (ICH), emphasizing avoidance of "overshoot" correction and SBP fluctuations. We evaluated the prognostic value of "SBP reduction with stability," a novel end point combining controlled blood pressure reduction and maintenance, using data from two large multinational clinical trials.
METHODS: We analyzed patients with ICH from Antihypertensive Treatment of Acute Cerebral Hemorrhage 2 and Intensive BP Reduction in Acute Cerebral Hemorrhage Trial 2 trials presenting with initial SBP 150-220 mm Hg. SBP reduction with stability was defined as achieving and maintaining SBP between 130 and 150 mm Hg within the first hour after randomization based on consecutive recordings. Outcomes included functional independence (modified Rankin scale 0-2) at 90 days and neurological deterioration within 24 h, adjusted for potential confounders.
RESULTS: Among 3,694 patients with ICH (2,781 patients from Intensive BP Reduction in Acute Cerebral Hemorrhage Trial 2 and 913 patients from Antihypertensive Treatment of Acute Cerebral Hemorrhage 2), 1,061 patients (28.7%) achieved SBP reduction with stability within 1 h. Patients had mean age 63.3 ± 12.9 years, baseline SBP 177.14 ± 18.28 mm Hg, and median hematoma volume of 10.78 mL (interquartile range 5.5-19.16). Achieving SBP reduction with stability significantly improved functional independence odds (odds ratio 1.38, 95% confidence interval 1.16-1.64) and reduced neurological deterioration odds (odds ratio 0.68, 95% confidence interval 0.53-0.88) after adjusting for initial SBP, Glasgow Coma Scale, age, sex, stroke history, hypertension, diabetes mellitus, study, ICH location, hematoma volume, and intraventricular hemorrhage presence.
CONCLUSIONS: Only 30% of patients with mild-to-moderate ICH achieved SBP reduction with stability within the first hour. This achievement was associated with improved functional outcomes and reduced early neurological deterioration. These findings suggest that SBP reduction with stability represents a valuable therapeutic target for future clinical trials in ICH management.
参考来源
- Qureshi AI, Baskett W, Martin RH, et al. Systolic Blood Pressure Reduction with Stability as a New Therapeutic Goal in Patients with Intracerebral Hemorrhage: Results of the Pooled Analysis of ATACH 2 and INTERACT 2 Trials. Neurocrit Care. 2025. PMID: 40394357. doi:10.1007/s12028-025-02277-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。